We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+26.22%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.23B
AUM Growth
+$240M
Cap. Flow
+$116M
Cap. Flow %
9.38%
Top 10 Hldgs %
61.25%
Holding
137
New
51
Increased
28
Reduced
20
Closed
23

Top Buys

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$70.5M
2
CELG
Celgene Corp
CELG
+$37.6M
3
RPRX
Repros Therapeutics Inc.
RPRX
+$27.9M
4
TSRO
TESARO, Inc.
TSRO
+$21.7M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$19.9M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$106M
2
BIIB icon
Biogen
BIIB
+$49.8M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$31.3M
4
STML
Stemline Therapeutics, Inc.
STML
+$16.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 76.94%
2 Financials 0.01%
3 Consumer Staples 0.01%
4 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDAS
126
DELISTED
MEDASSETS INC COM STK (DE)
MDAS
– –
-1,150
Closed -$20K
SLXP
127
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-148,250
Closed -$9.81M
LPDX
128
DELISTED
LIPOSCIENCE INC COM
LPDX
– –
-82,292
Closed -$575K
QCOR
129
CALL
DELISTED
QUESTCOR PHARMA INC
QCOR
– –
0
– -$2.27M
HMA
130
DELISTED
HEALTH MGMT ASSOC INC CL-A
HMA
– –
-1,265
Closed -$20K
VPHM
131
DELISTED
VIROPHARMA INC
VPHM
– –
-48,300
Closed -$1.38M
ELN
132
DELISTED
ELAN CORP ADS(RP1 ORD4IRISH PN
ELN
– –
-483,000
Closed -$6.83M
OPTR
133
PUT
DELISTED
OPTIMER PHARMACEUTICALS, INC. COM STK
OPTR
– –
0
– -$7.18M
BDSI
134
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-477,600
Closed -$1.94M
SHPG
135
DELISTED
Shire pic
SHPG
– –
-80,800
Closed -$7.68M
2 3 4 5
6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2013 Portfolio in Review

As of Q3 2013, Perceptive Advisors held 137 positions worth $1.23B, up 24% from $992M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Perceptive Advisors deployed $116M of net new capital in Q3 2013, opening 51 new positions and adding to 28 existing holdings. Its largest new stake was ONYX PHARMACEUTICALS INC: 556,944 shares worth $69.5M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 80% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Aegerion Pharmaceuticals, an estimated $106M trimmed.

  • Perceptive Advisors's largest Q3 2013 buy was ONYX PHARMACEUTICALS INC: 556,944 shares worth $69.5M.
  • Perceptive Advisors added most to Celgene Corp in Q3 2013, an estimated $37.6M increase.
  • Perceptive Advisors's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $106M.
  • Perceptive Advisors fully exited Biogen in Q3 2013, selling an estimated $49.8M.
  • Perceptive Advisors's ten largest holdings make up 61% of its $1.23B portfolio in Q3 2013.
  • Perceptive Advisors opened 51 new positions and closed 23 in Q3 2013.
  • Perceptive Advisors's portfolio value rose 24% quarter-over-quarter to $1.23B.

Based on Perceptive Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.